Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report

Abstract Background Pulmonary sarcomatoid carcinoma is a rare non-small-cell lung cancer (NSCLC) subtype with a poor prognosis. In the phase III PACIFIC study, durvalumab significantly improved progression-free survival and overall survival versus placebo, in patients with stage III NSCLC who do not...

Full description

Bibliographic Details
Main Authors: Kazumi Nishino, Kei Kunimasa, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Hanako Kuhara, Toru Kumagai
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Pharmacology and Toxicology
Subjects:
Pulmonary sarcomatoid carcinoma
Durvalumab
Pembrolizumab
PD-L1
PD-L2
Online Access:http://link.springer.com/article/10.1186/s40360-020-00404-7

Internet

http://link.springer.com/article/10.1186/s40360-020-00404-7

Similar Items